ReviewJournal of pathology and translational medicine2020
HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.
Review in Journal of pathology and translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 3 syntheses or guidelines pooled it, 257 citations in OpenAlex.
- New insights on Galectin-9 expression in cancer prognosis: An updated systemic review and meta-analysis.PloS one · 2025Pooled it
- Consensus Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2)-Low Testing in Breast Cancer in Malaysia.Cancers · 2024Guideline
- Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis.Systematic reviews · 2022Pooled it
- Detection of HER2 expression usingBreast cancer research : BCR · 2024Trial
- [Clinicopathological characteristics of human epidermal growth factor receptor-2 1+ cases in breast cancer].Revista medica del Instituto Mexicano del Seguro Social · 2026Observational
- Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.La Radiologia medica · 2026Article
- HER2-Low Gastric and Gastroesophageal Junction Adenocarcinoma: From Assessment to Treatment Strategies.International journal of molecular sciences · 2026Review
- HER2 Score-Aware Virtual Immunohistochemistry via Non-Contrastive Multi-Task Translation.Diagnostics (Basel, Switzerland) · 2026Article
- HScore as a diagnostic tool in ERBB2 equivocal (immunohistochemistry 2+) breast cancer.Laboratory medicine · 2026Article
- Article
- Improving HER2 Diagnostics with Digital Real-Time PCR for Ultrafast, Precise Prediction of Anti-HER2 Therapy Response in Patients with Breast Cancer.Small methods · 2026Article
- The impact of HER2 discordance on patient prognosis following anti-HER2 neoadjuvant therapy for HER2-positive breast cancer.Frontiers in oncology · 2026Article
- Impact of Ethnic Differences and HER2 Protein Expression on the Age at Breast Cancer Diagnosis: A Mixed Methods Study.Cancer management and research · 2026Article
- Article
- Real-world response rates in patients with human epidermal growth factor receptor 2-positive breast cancer after neoadjuvant treatment using dual human epidermal growth factor receptor 2 blockade.Frontiers in oncology · 2026Article
- Concurrent genomic assessment of circulating tumour cells and ctDNA to guide therapy in metastatic breast cancer.BMC cancer · 2025Article
- Validation of ancillary procedures on formalin liquid fixed aspiration cytologic samples: from minimum to maximum.American journal of clinical pathology · 2025Article
- The relationship of ST6GAL1 with clinicopathological and prognostic factors in breast carcinomas.Saudi medical journal · 2025Article
- Digital pathology enabling lean management of HER2/neu testing in breast Cancer.Journal of pathology informatics · 2025Article
- Unveiling Metabolic Signatures as Potential Biomarkers in Common Cancers: Insights from Lung, Breast, Colorectal, Liver, and Gastric Tumours.Biomolecules · 2025Review
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2 gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive marker for treatment benefits from HER2 targeted therapy and thus, HER2 testing is a routine practice for newly diagnosed breast cancer in pathology. Currently, HER2 immunohistochemistry (IHC) is used for a screening test, and in situ hybridization is used as a confirmation test for HER2 IHC equivocal cases. Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer. During HER2 interpretation, some pitfalls such as intratumoral HER2 heterogeneity and increase in chromosome enumeration probe 17 signals may lead to inaccurate assessment of HER2 status. Moreover, HER2 status can be altered after neoadjuvant chemotherapy or during metastatic progression, due to biologic or methodologic issues. This review addresses recent updates of ASCO/CAP guidelines and factors complicating in the interpretation of HER2 status in breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.